Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 8/20 | 0.56 |
| ▸ | BCHE | P06276 | 7/20 | 0.56 |
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876506 | 0.94 | TSHR (0.57) | MEN1KMT2AACHEBCHECNR1 | |
| SCHEMBL14087167 | 0.87 | HDAC3 (0.53) | MEN1KMT2AACHEBCHE | |
| SCHEMBL4883723 | 0.84 | HDAC3 (0.50) | ACHEBCHELTA4H | |
| SCHEMBL14498741 | 0.83 | HDAC3 (0.78) | — | |
| SCHEMBL14498747 | 0.81 | HDAC3 (0.78) | — | |
| SCHEMBL4884072 | 0.78 | TSHR (0.68) | MEN1KMT2AACHEBCHECNR1 | |
| SCHEMBL14498752 | 0.78 | HDAC3 (0.78) | — | |
| SCHEMBL4877516 | 0.77 | TSHR (0.63) | MEN1KMT2AACHEBCHECNR1 | |
| SCHEMBL14569771 | 0.76 | TSHR (0.69) | MEN1KMT2AACHEBCHECNR1 | |
| SCHEMBL7234281 | 0.76 | TSHR (0.64) | MEN1KMT2AACHEBCHELTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | KALYPSYS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | KALYPSYS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | KALYPSYS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1819669-A2 | NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006063294-A2 | NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006063294-A2 | NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | HDAC1, HDAC10, HDAC6 | MEN1 2700/4885KMT2A 206/4885ACHE 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.